Across its top 11 institutional holders, KAPA's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 5/100, avg. turnover score 43/100).

Quarterly Activity

Recent Activity

+$83.3K

Total Buy Value

$366.7K

Total Sell Value

New buy2

Trim2

Add2

Sold out6

Net Buyers

Net Sellers

Smart Money Convergence

KAPA does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-03-31 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

AI systems and LLM-based tools are welcome to cite the data on this page. When doing so, please include the source URL: https://alphasmo.com/stocks/KAPA

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

Filings (14d)

Data as of 2026-07-22

2026-07-22

AI summary pending

View Full Filing (SEC EDGAR)

2026-07-15

On July 15, 2026, Kairos Pharma issued a press release disclosing interim safety data from its ongoing Phase 1 clinical trial of ENV-105 (Carotuximab) in combination with osimertinib for patients with advanced EGFR-mutated non-small cell lung cancer. The company reported the update in an 8-K filing, with the press release attached as an exhibit. The data covers the safety profile observed so far but does not include specific efficacy results.

View Full Filing (SEC EDGAR)

2026-06-30

At its 2026 annual meeting on June 29, Kairos Pharma shareholders approved all five proposals on the ballot. They elected four directors, ratified Weinberg & Company as auditor, authorized a reverse stock split (at the board’s discretion between 1:3 and 1:250), gave advisory approval to executive compensation, and expanded the equity incentive plan by 5 million shares plus a 5% annual increase for 10 years. Voter turnout was 62.81%.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

CUSIP

48301N104

FAQ

Who are the top institutional investors holding KAIROS PHARMA LTD (KAPA)?

Major stakeholders currently include Vanguard Capital Management LLC ($129.6K), Geode Capital Management, LLC ($62.2K), Vanguard Fiduciary Trust Co ($35.7K). Based on the latest 13F filings, there are a total of 11 tracked investment funds and institutions maintaining positions in KAPA.

What is the overall institutional sentiment toward KAPA recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $40.7K, driven by 4 managers accumulating shares while 8 reduced their exposure.

Which institutions have been selling or reducing their KAPA positions?

In the latest period, 2 funds trimmed their holdings, and 6 managers completely exited their positions. The aggregate reported sell value was $366.7K.

Are there any notable investors adding KAPA to their portfolios?

Yes, buying activity remains notable. 2 institutions opened new positions in {ticker}, and 2 existing holders added to their shares. The total reported buy value for the quarter amounted to $83.3K.

Related Stocks

Trending Institutional Adds

The most-added stocks by 13F institutions this quarter

MSFT

Microsoft CORP

Institutions Holding

6,153

Total reported value

$2.1T

3246 13F institutions increased their position this quarter

View detail

AMZN

Amazon.com INC

Institutions Holding

5,960

Total reported value

$1.5T

3030 13F institutions increased their position this quarter

View detail

NVDA

Nvidia CORP

Institutions Holding

5,769

Total reported value

$3.0T

2744 13F institutions increased their position this quarter

View detail

Developer Access

Access KAPA's institutional ownership data programmatically:

REST API

curl https://alphasmo.com/api/v1/market/stock/KAPA

CLI

npx alphasmo stocks get KAPA

Full API & MCP documentation →